Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential
Management Reshuffle And 20% Headcount Cut
Executive Summary
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
You may also be interested in...
Lung Cancer Failure Isn't The End For Merck KGaA And GSK's Bintrafusp
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
Immunocore Aims For $100m IPO After Immunotherapy Success
The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports